
|Videos|April 14, 2023
Understanding and Mitigating the Cardiometabolic Risks of ADT
Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to Enolen for localized prostate cancer
2
Trial to assess testosterone undecanoate in older men with hypogonadism
3
Pivotal trial of Butterfly Device for BPH reaches final completion
4
Genomic classifier score linked with focal therapy outcomes in prostate cancer
5






















